Last reviewed · How we verify
Heparin administration
Heparin is an anticoagulant that inhibits blood clotting by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.
Heparin is an anticoagulant that inhibits blood clotting by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors. Used for Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prophylaxis, Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.
At a glance
| Generic name | Heparin administration |
|---|---|
| Sponsor | Anemia Working Group Romania |
| Drug class | Anticoagulant |
| Target | Antithrombin III (indirect); Thrombin and Factor Xa (downstream targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin binds to and potentiates antithrombin III, a natural inhibitor of coagulation proteases. This complex rapidly inactivates thrombin (Factor IIa) and Factor Xa, preventing the formation of fibrin clots and the propagation of thrombosis. Heparin is used both therapeutically to treat existing clots and prophylactically to prevent clot formation in high-risk patients.
Approved indications
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prophylaxis
- Acute coronary syndrome
- Atrial fibrillation with thromboembolism risk
- Thromboprophylaxis in surgical and medical patients
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis
- Injection site reactions
- Osteoporosis (with prolonged use)
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology (PHASE4)
- Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS (NA)
- EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin administration CI brief — competitive landscape report
- Heparin administration updates RSS · CI watch RSS
- Anemia Working Group Romania portfolio CI